Pantoprazole Use in Invasively Ventilated Patients With Septic Shock: A Protocol and Statistical Analysis Plan
Study context
- Population
- Invasively ventilated critically ill adults with septic shock (vasopressors or inotropes at baseline plus admitting diagnosis of infection by APACHE III categories) enrolled in REVISEREVISE enrolled 4821 in 68 ICUs
- Planned comparison
- IV pantoprazole 40 mg once daily vs placebo
- Primary endpoint
- Clinically important upper gastrointestinal bleeding in the ICU (primary safety outcome: all-cause mortality within 90 days)
- Follow-up
- 90 days after randomization
Methodological detailspost hoc extended subgroup analysis, international, blinded, randomized, Analyses adjusted for prehospital acid suppression; mortality analyses additionally adjusted for APACHE II score
- Post hoc extended subgroup analysis
- International
- Blinded
- Randomized
- Analyses adjusted for prehospital acid suppression; mortality analyses additionally adjusted for APACHE II score
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Pantoprazole Use in Invasively Ventilated Patients With Septic Shock: A Protocol and Statistical Analysis Plan. Acta Anaesthesiol Scand. Published 26 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →